![](/img/cover-not-exists.png)
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Schafer, Eric S., Rau, Rachel E., Berg, Stacey, Liu, Xiaowei, Minard, Charles G., D'Adamo, David, Scott, Rachael, Reyderman, Larisa, Martinez, Gresel, Devarajan, Sandhya, Reid, Joel M., Fox, ElizabethLanguage:
english
Journal:
Pediatric Blood & Cancer
DOI:
10.1002/pbc.27066
Date:
May, 2018
File:
PDF, 415 KB
english, 2018